Second-line immunosuppressant administration for steroid-refractory immune-related adverse events in patients with lung cancer.

ABSTRACT:

Background

Evidence for use of second-line immunosuppressants for immune-related adverse events (irAEs) is inadequate. Therefore, a multicenter analysis should assess the efficacy of second-line immunosuppressants for severe irAEs associated with different malignant diseases.

Methods

This descriptive study aims to investigate the effects of second-line immunosuppressants on corticosteroid-refractory irAEs in patients with lung cancer. We analyzed the effects of second-line immunosuppressants on underlying lung cancer and associated adverse effects.

Results

Our study included 4589 patients who had received immune checkpoint inhibitor treatment, with 73 patients (1.6%) developing irAEs requiring second-line immunosuppressants. The most commonly observed irAE was pneumon

SUBMITTER: Ogusu S 

PROVIDER: S-EPMC10576678 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature